Patent US5403713A successfully refreshed from Google Patents.
US5403713A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antibodies specific for ELAM-1 and the use thereof
Assignee: The Brigham and Women's Hospital Inc
•
Filing: 1993-08-05
•
Granted: 1995-04-04
•
Expires: 2013-08-05
Abstract
Abstract The invention relates to a method for detecting ELAM-1 expression in a patient comprising (i) administration of a detectable amount of a labelled ELAM-1 specific antibody (or an anti-ELAM 1 antibody fragment) and a pharmaceutically acceptable carrier, and (ii) detecting the label. ELAM-1 is an endothelial cell surface glycoprotein which participates in endothelialleukocyte adhesion. Induction of ELAM-1 expression has been detected on endothelial cells at sites of inflammation.
Inventors
- 👤 Michael P. Bevilacqua
- 👤 Michael A. Gimbrone
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:55
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2851; C07K16/2854; A; A61; A61K; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6835; A61K47/6849; A61P; A61P29/00; A61P31/00; A61P31/04; A61P35/00; C07K14/00; C07K14/435; C07K14/705; C07K14/7056; C07K14/70564; A61K38/00
Claims Analysis
Total Claims: 2
Claim 1
Independent Claim
58 words
A method for detecting ELAM-1 expression in a patient, comprising (i) administering to said patient for a time, and under conditions sufficient for binding, a pharmaceutical composition comprising a detectable amount of a labelled anti-ELAM-1 H18/7 monoclonal antibody, or a labelled antibody fragment comprising an Fab domain thereof, and a pharmaceutically acceptable carrier, and (ii) detecting said label.
Claim 2
Independent Claim
58 words
A method for detecting ELAM-1 expression in a patient, comprising (i) administering to said patient for a time, and under conditions sufficient for binding, a pharmaceutical composition comprising a detectable amount of a labelled anti-ELAM-1 H18/7 monoclonal antibody, or a labelled antibody fragment comprising an Fab domain thereof, and a pharmaceutically acceptable carrier, and (ii) detecting said label.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1998-04-03 | 1998-10-03 | 1999-04-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2002-04-03 | 2002-10-03 | 2003-04-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2006-04-03 | 2006-10-03 | 2007-04-04 | $7700.00 | Window Closed / Lapsed |